| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | CID-5951923 | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.007 | 0.9 |
| mRNA | CEP-701 | FIMM | pan-cancer | AAC | -0.017 | 0.9 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | -0.0072 | 0.9 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | TG-101348 | GDSC1000 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | piperlongumine:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | tubastatin A | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.9 |
| mRNA | BMS-270394 | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |